Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
Open Access
- 1 February 2019
- journal article
- research article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 13, 261-272
Abstract
Purpose: Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an increasingly significant role in treatment decision-making. This study aims to evaluate the degree of adherence, along with other variables that may influence this adherence, in Spain. Methods: A cross-sectional study was conducted with 157 MS patients with disease-modifying treatments. Adherence was assessed using the Morisky Green scale, and other related factors were measured using a questionnaire that addressed demographics, disease characteristics, global perception of pathology, impact of medication on patient’s life, and treatment decision-making. Results: The adherence rate was 71% and was associated with the following variables: older age, more treatments received, time to diagnosis 5–10 years, absence of exacerbations, better cognitive status, being married/in a union, clear information about the disease, and higher treatment satisfaction. The main cause for non-compliance was forgetfulness (27%). Conclusion: The adherence rate is acceptable. It is widely known that treatment satisfaction is related to adherence. In our study, patients’ level of satisfaction was higher with oral treatments. However, oral administration showed a greater lack of adherence. The main cause of lack of adherence was forgetfulness. In relation to other variables, cognitive status and family support showed a correlation with treatment adherence.Keywords
This publication has 27 references indexed in Scilit:
- Multiple sclerosis: Prospects and promiseAnnals of Neurology, 2013
- Facilitating Medication Adherence in Patients with Multiple SclerosisInternational Journal of MS Care, 2013
- Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in SpainPLOS ONE, 2012
- Multiple sclerosisJournal of Clinical Investigation, 2012
- Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysisPatient Preference and Adherence, 2011
- The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosisEuropean Journal of Neurology, 2010
- A meta-analysis of the association between adherence to drug therapy and mortalityBMJ, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- Adherence to Disease-Modifying Therapy in Multiple Sclerosis: Part IRehabilitation Nursing Journal, 2001
- Concurrent and Predictive Validity of a Self-reported Measure of Medication AdherenceMedical Care, 1986